Geneos Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Geneos Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,500	Closed	-$4K	–	2085
2017 Q1	$4K	Hold	2,500	–	–	﹤0.01%	1724
2016 Q4	$2K	Hold	2,500	–	–	﹤0.01%	1832
2016 Q3	$2K	Hold	2,500	–	–	﹤0.01%	1755
2016 Q2	$1K	Hold	2,500	–	–	﹤0.01%	1729
2016 Q1	$3K	Buy	+2,500	New	+$3.88K	﹤0.01%	1593

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geneos Wealth Management's CPRX Position: Q2 2017 in Review

Geneos Wealth Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2017, closing a stake of 2,500 shares — an estimated $4K sold.

Geneos Wealth Management first reported a position in CPRX in Q1 2016 and held it in 5 quarters. The position peaked at $4K in Q1 2017. 69 funds tracked by Wall St. Rank hold CPRX as of Q2 2017.

Geneos Wealth Management reported no remaining Catalyst Pharmaceutical position as of Q2 2017 after selling out during the quarter.
Geneos Wealth Management sold 2,500 Catalyst Pharmaceutical shares in Q2 2017, an estimated $4K.
Geneos Wealth Management first reported a position in Catalyst Pharmaceutical in Q1 2016 and held it in 5 quarters.
Geneos Wealth Management's Catalyst Pharmaceutical position peaked at $4K in Q1 2017.
69 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2017.

Based on Geneos Wealth Management's 13F filing for Q2 2017, filed 7 Sep 2021.